Drugs / Mobilan
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02654938 | Jul 2015 → Sep 2017 | prostate cancer | Panacela Labs LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02844699 | Jul 2016 → Jan 2018 | prostate cancer | Panacela Labs LLC | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mobilan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02654938 ↗ |
| Known as | M-VM3 | “Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.” NCT02844699 ↗1“Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer” NCT02654938 ↗ |
| Route | Other | “administered directly into the prostate” NCT02654938 ↗ |
| Target | TLR5 | “directs expression of both toll-like receptor 5 (TLR5)” NCT02844699 ↗ |